Mangrove Partners Iovance Biotherapeutics, Inc. Transaction History

Mangrove Partners

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$28.04 - $50.26 $10.6 Million - $19.1 Million	-379,188 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$27.75 - $36.3 $8.75 Million - $11.5 Million	315,465 Added 495.06%	379,188 $12.5 Million
Q2 2020 Aug 14, 2020	SELL	$27.21 - $41.0 $21.8 Million - $32.8 Million	-799,654 Reduced 92.62%	63,723 $1.75 Million
Q1 2020 May 15, 2020	SELL	$19.54 - $38.85 $5.77 Million - $11.5 Million	-295,239 Reduced 25.48%	863,377 $25.8 Million
Q4 2019 Feb 14, 2020	SELL	$17.95 - $29.41 $612,418 - $1 Million	-34,118 Reduced 2.86%	1,158,616 $32.1 Million
Q3 2019 Nov 14, 2019	BUY	$17.99 - $26.0 $21.5 Million - $31 Million	1,192,734 New	1,192,734 $21.7 Million

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.35B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Mangrove Partners, based on Form 13F filings with the SEC.

Stay updated on Mangrove Partners with notifications on news.